view original post

BioNTech SE (NASDAQ:BNTX) has seen 1.34 million shares traded in the recent trading session. The company, currently valued at $52.08B, closed the recent trade at $215.70 per share which meant it gained $3.86 on the day or 1.82% during that session. The BNTX stock price is -115.11% off its 52-week high price of $464.00 and 58.14% above the 52-week low of $90.29. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.45 million shares traded. The 3-month trading volume is 3.23 million shares.

Sporting 1.82% in the green today, the stock has traded in the red over the last five days, with the highest price hit on Friday, 01/07/22 when the BNTX stock price touched $215.70 or saw a rise of 7.63%. Year-to-date, BioNTech SE shares have moved -17.83%, while the 5-day performance has seen it change -17.83%. Over the past 30 days, the shares of BioNTech SE (NASDAQ:BNTX) have changed -27.44%. Short interest in the company has seen 2.17 million shares shorted with days to cover at 0.52.

3 Tiny Stocks Primed to Explode The world’s greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We’ve set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored

Wall Street analysts have a consensus price target for the stock at $274.02, which means that the shares’ value could jump 21.28% from the levels at last check today. The projected low price target is $155.38 while the price target rests at a high of $353.68. In that case, then, we find that the latest price level in today’s session is -63.97% off the targeted high while a plunge would see the stock lose 27.96% from the levels at last check today.

BioNTech SE (BNTX) estimates and forecasts

Figures show that BioNTech SE shares have outperformed across the wider relevant industry. The company’s shares have lost -1.78% over the past 6 months, with this year growth rate of 55,942.86%, compared to 7.80% for the industry. Other than that, the company has, however, increased its growth outlook for the 2022 fiscal year revenue. Growth estimates for the current quarter are 343.80% and 88.50% for the next quarter. Revenue growth from the last financial year stood is estimated to be 3,229.50%.

7 analysts offering their estimates for the company have set an average revenue estimate of $4.57 billion for the current quarter. 4 have an estimated revenue figure of $4.74 billion for the next quarter concluding in Mar 2022. Year-ago sales stood $422.55 million and $1.75 billion respectively for this quarter and the next, and analysts expect sales will grow by 981.70% for the current quarter and 170.10% for the next.

BNTX Dividends

BioNTech SE is expected to release its next earnings report on November 09 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.

BioNTech SE (NASDAQ:BNTX)’s Major holders

Insiders own 66.88% of the company shares, while shares held by institutions stand at 17.22% with a share float percentage of 51.99%. Investors are also buoyed by the number of investors in a company, with BioNTech SE having a total of 525 institutions that hold shares in the company. The top two institutional holders are Baillie Gifford and Company with over 6.35 million shares worth more than $1.73 billion. As of Sep 29, 2021, Baillie Gifford and Company held 2.62% of shares outstanding.

The other major institutional holder is Primecap Management Company, with the holding of over 4.28 million shares as of Sep 29, 2021. The firm’s total holdings are worth over $1.17 billion and represent 1.77% of shares outstanding.

>> 7 Top Picks for the Post-Pandemic Economy <<

Also the top two Mutual Funds that are holding company’s shares are Vanguard Horizon Fund-Capital Opportunity Fund and Primecap Odyssey Aggressive Growth Fund. As of Sep 29, 2021, the former fund manager holds about 0.85% shares in the company for having 2.06 million shares of worth $561.8 million while later fund manager owns 1.64 million shares of worth $455.92 million as of Oct 30, 2021, which makes it owner of about 0.67% of company’s outstanding stock.